BRIEF—ThromboGenics becomes Oxurion

Belgian biotech ThromboGenics has announced it will change its name to Oxurion in the next few weeks. The stock ticker symbol will change to OXUR.

Chief executive Patrik De Haes said: “The new name, Oxurion, is designed to better reflect our ambition to deliver best in class therapies for back of the eye disorders,” and “we are also expanding our drug development efforts into new back of the eye indications where there is clear need for improved therapeutic options.”